Seeing Red: Clinical Assessment Tools for Clinical Trial Decision Support
Launched by SCOTIADERM · Feb 26, 2023
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Seeing Red," is focused on improving how nurses document and assess certain skin conditions caused by moisture, specifically incontinence-associated dermatitis (IAD) and intertrigo (ITD). These conditions can lead to rashes and skin damage, and the study aims to test a new structured tool that helps nurses describe and track these skin issues more accurately. By using a standardized approach, the trial hopes to make it easier to monitor how these rashes develop and respond to treatment, ensuring that all nurses assess the conditions in a consistent way.
To participate in this study, you need to be at least 18 years old and diagnosed with either IAD or ITD, with an expected hospital stay of at least seven days. You'll be asked to provide consent for daily photographs of your rash to help with tracking its healing. Participants can expect to be part of a process that not only enhances their care but also contributes to better nursing practices in the future. The trial is not yet recruiting participants, so it's still in the early stages of planning.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age ≥ 18 years
- • Intertrigo (ITD) and or incontinence-associated dermatitis (IAD)
- • Expected length of stay of seven (7) days
- • life expectancy greater than one week
- • written informed consent by the patient or his/her representative including explicit consent to take daily photographs of the rash associated with MASD.
- Exclusion Criteria:
- • known allergy to standard MASD treatments
- • life expectancy less than seven days
- • complex skin disorders
About Scotiaderm
Scotiaderm is a dedicated clinical trial sponsor focused on advancing dermatological research and innovation. Committed to enhancing patient outcomes, Scotiaderm specializes in the development and evaluation of novel therapies for a range of skin conditions. With a robust portfolio of clinical trials, the organization collaborates with leading healthcare professionals and institutions to ensure rigorous study design and execution. Scotiaderm prioritizes safety, efficacy, and ethical standards, striving to contribute meaningful advancements in dermatology and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials